$MOBI

Green Park & Golf Ventures II, LLC sold 6,731 shares of MOBI (indirect holdings)

Green Park & Golf Ventures II, LLC sold 6,731 indirectly-held shares of Mobia Medical, Inc. (MOBI) on 2026-05-11.

Original reporting
SEC EDGAR · Green Park & Golf Ventures II, LLC
Published Jun 29, 2026, 11:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MOBI
Neutral
medium confidence
Mentioned
$MOBI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MOBINeutralLow
01

Why it matters

A 10% owner sold 6,731 shares on 2026-05-11; the filing does not disclose sale price/value and does not cite a 10b5-1 plan, reducing interpretability for traders.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale without value disclosure is unlikely to drive a major repricing.

03

What to watch

No total value or execution price is provided, and the absence of a 10b5-1 plan does not, by itself, confirm bearish intent without additional context (e.g., prior trades, pattern, or follow-on buys).

Relevance 4/10Novelty 4/10Timing: after-hours/filing update on 2026-06-29 (Form 4)

Background

The article is an SEC Form 4 insider transaction disclosure for Mobia Medical, Inc. (MOBI).

Company-level read

Ticker impact

$MOBINeutralMedium confidence
Context

Green Park & Golf Ventures II, LLC (10% owner) sold 6,731 shares of Mobia Medical via an open-market Form 4 filed June 29.

Expected impact

Low likelihood of a sustained price move; any reaction would likely be short-lived and sentiment-driven.

Evidence & confidence

The filing discloses direction (sale) and share count, but provides no price/total value and no 10b5-1 plan, limiting inference about materiality.

Market effects

Minimal; this is company-specific insider transaction data with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale may be non-informational (liquidity/tax/portfolio rebalancing), especially since the filing lacks disclosed price/value and any stated reason.

Key entities

  • Mobia Medical, Inc.

    Subject of the Form 4 insider transaction; ticker MOBI.

  • Green Park & Golf Ventures II, LLC

    10% owner who executed an open-market sale of 6,731 shares (indirect holdings).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.

$MOBIMedAI 8/10

Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.

$MOBIMed

Mobia Medical, Inc. (MOBI): Results of Operations and Financial Condition

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial re

$MOBIMedAI 8/10

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.